Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Decrease in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the recipient of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 2,900,000 shares, a drop of 18.1% from the October 31st total of 3,540,000 shares. Based on an average trading volume of 321,000 shares, the days-to-cover ratio is presently 9.0 days. Approximately 6.0% of the shares of the company are short sold.

Institutional Investors Weigh In On Astria Therapeutics

A number of institutional investors have recently made changes to their positions in ATXS. Quest Partners LLC increased its stake in shares of Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares during the period. PDT Partners LLC bought a new stake in Astria Therapeutics in the 3rd quarter valued at $140,000. SG Americas Securities LLC acquired a new position in Astria Therapeutics in the 3rd quarter valued at $155,000. Price T Rowe Associates Inc. MD bought a new position in Astria Therapeutics during the 1st quarter worth $200,000. Finally, Hsbc Holdings PLC acquired a new stake in shares of Astria Therapeutics during the second quarter worth $171,000. Institutional investors own 98.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ATXS. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Thursday, November 14th. Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday, August 13th. Oppenheimer upped their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. Finally, Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Stock Performance

ATXS traded down $0.11 on Friday, reaching $10.39. The company had a trading volume of 139,469 shares, compared to its average volume of 601,783. The stock has a market cap of $586.35 million, a P/E ratio of -4.97 and a beta of 0.71. Astria Therapeutics has a fifty-two week low of $4.50 and a fifty-two week high of $16.90. The company’s fifty day moving average is $11.10 and its 200 day moving average is $10.62.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.